BerandaB1MR34 • BVMF
add
Biomarin Pharmaceutical Inc Bdr
Tutup sebelumnya
R$165,45
Rentang tahun
R$165,45 - R$258,34
Kapitalisasi pasar
11,37 M USD
Volume Rata-Rata
47,00
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 745,14 jt | 14,84% |
Biaya operasional | 210,96 jt | -12,17% |
Laba bersih | 185,69 jt | 109,43% |
Margin laba bersih | 24,92 | 82,43% |
Penghasilan per saham | 1,13 | 59,15% |
EBITDA | 245,96 jt | 132,45% |
Tarif pajak efektif | 22,01% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 1,27 M | 21,57% |
Total aset | 7,15 M | 3,99% |
Total liabilitas | 1,35 M | -24,76% |
Total ekuitas | 5,79 M | — |
Saham yang beredar | 191,78 jt | — |
Harga terhadap nilai buku | 5,48 | — |
Tingkat pengembalian aset | 7,92% | — |
Tingkat pengembalian modal | 8,82% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 185,69 jt | 109,43% |
Kas dari operasi | 174,39 jt | 271,28% |
Kas dari investasi | -28,24 jt | -98,36% |
Kas dari pembiayaan | -38,78 jt | 9,38% |
Perubahan kas bersih | 105,96 jt | 1.403,17% |
Arus kas bebas | 102,79 jt | 376,04% |
Tentang
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Didirikan
Mar 1997
Kantor pusat
Situs
Karyawan
3.040
